Abstract
There is a paucity of treatment options for patients who have failed multiple biologics. A drawback of biologic therapies is their selectivity in targeting a single pathway. We report the use of dual biologic therapy with vedolizumab and ustekinumab for three highly refractory patients who previously failed both of these medications as monotherapy. The dual biologic therapy led to the closure of a recto-vaginal fistula and restoration of continuity after takedown of a stoma.
Original language | English |
---|---|
Pages (from-to) | 372-374 |
Number of pages | 3 |
Journal | European Journal of Gastroenterology and Hepatology |
Volume | 34 |
Issue number | 4 |
DOIs | |
State | Published - 1 Apr 2022 |
Keywords
- Crohn's disease
- dual biologic therapy
- multidrug refractory Crohn's